Two-part accommodating intraocular lens device

Information

  • Patent Grant
  • 11464622
  • Patent Number
    11,464,622
  • Date Filed
    Monday, November 25, 2019
    4 years ago
  • Date Issued
    Tuesday, October 11, 2022
    2 years ago
Abstract
A two-part accommodating intraocular lens (IOL) device for implantation in a capsular bag of a patient's eye. The IOL device includes a primary lens assembly and a power changing lens. The primary lens assembly includes a fixed lens and a peripherally disposed centration member. The centration member has a circumferential distal edge and a first coupling surface adjacent the circumferential distal edge. The power changing lens has an enclosed, fluid- or gel-filled lens cavity and haptic system disposed peripherally of the lens cavity. The haptic system has a peripheral engaging edge configured to contact the capsular bag and a second coupling surface. The first and second coupling surfaces are in sliding contact with one another to permit movement of the power changing lens relative to the primary lens assembly and also to maintain a spaced relationship between the fixed lens and the lens cavity during radial compression of the power changing lens.
Description
FIELD OF THE INVENTION

The invention relates generally to an accommodating intraocular lens device and, more particularly, to an accommodating intraocular lens device configured for implantation in a lens capsule of a subject's eye.


BACKGROUND

Surgical procedures on the eye have been on the rise as technological advances permit for sophisticated interventions to address a wide variety of ophthalmic conditions. Patient acceptance has increased over the last twenty years as such procedures have proven to be generally safe and to produce results that significantly improve patient quality of life.


Cataract surgery remains one of the most common surgical procedures, with over 16 million cataract procedures being performed worldwide. It is expected that this number will continue to increase as average life expectancies continue to rise. Cataracts are typically treated by removing the crystalline lens from the eye and implanting an intraocular lens (“IOL”) in its place. As conventional IOL devices are primarily focused for distance visions, they fail to correct for presbyopia and reading glasses are still required. Thus, while patients who undergo a standard IOL implantation no longer experience clouding from cataracts, they are unable to accommodate, or change focus from near to far, from far to near, and to distances in between.


Surgeries to correct refractive errors of the eye have also become extremely common, of which LASIK enjoys substantial popularity with over 700,000 procedures being performed per year. Given the high prevalence of refractive errors and the relative safety and effectiveness of this procedure, more and more people are expected to turn to LASIK or other surgical procedures over conventional eyeglasses or contact lens. Despite the success of LASIK in treating myopia, there remains an unmet need for an effective surgical intervention to correct for presbyopia, which cannot be treated by conventional LASIK procedures.


As nearly every cataract patient also suffers from presbyopia, there is convergence of market demands for the treatment of both these conditions. While there is a general acceptance among physicians and patients of having implantable intraocular lens in the treatment of cataracts, similar procedures to correct for presbyopia represent only 5% of the U.S. cataract market. There is therefore a need to address both ophthalmic cataracts and/or presbyopia in the growing aging population.


BRIEF SUMMARY

The two-part accommodating IOL devices disclosed herein provides for a number of advantages owing to its separate two-part construction. Implantation of the IOL device requires a significantly reduced incision size, as the two parts of the IOL device are implanted separately and thus significantly reducing the delivery profile for implantation. The reduced incision size provides for a number of advantages, including obviating the need for anesthesia and sutures to close the incision site and improved surgical outcomes.


Additionally, greater control is afforded with respect to adjusting the sizing and the power of the IOL during surgery. Implanting the primary lens into the lens capsule will provide the physician an impression as to the size of the patient's lens capsule and will thus help verify the correct size of the power changing lens that will subsequently be implanted.


In one embodiment, a two-part accommodating intraocular lens (IOL) device for implantation in a capsular bag of a patient's eye is described. The IOL device comprises a primary lens assembly and a power changing lens assembly. The primary lens assembly comprises a fixed lens and a centration member disposed peripherally of the fixed lens. The centration member has a circumferential distal edge and a first coupling surface adjacent the circumferential distal edge. The power changing lens comprises an enclosed and fluid- or gel-filled lens cavity and a haptic system disposed peripherally of the lens cavity. The haptic system has a peripheral engaging edge configured to contact the capsular bag and a second coupling surface facing the first coupling surface and located adjacent the peripheral engaging edge. The first and second coupling surfaces are in sliding contact with one another to permit movement of the power changing lens relative to the primary lens assembly. The first and second coupling surfaces maintain a spaced relationship between the fixed lens and the lens cavity when the power changing lens is radially compressed.


In accordance with a first aspect, a diameter d1 of the power changing lens is greater than a diameter d2 of the primary lens assembly in the absence of radial compression.


In accordance with a second aspect, the fixed lens does not change shape or curvature during accommodation.


In accordance with a third aspect, the lens cavity changes both shape and curvature during accommodation.


In accordance with a fourth aspect, the fixed lens and the lens cavity are positive power lenses.


In accordance with a fifth aspect, the fluid- or gel-filled lens cavity is a biconvex lens.


In accordance with a sixth aspect, the fixed lens assembly comprises a squared edge located circumferentially around the fixed lens outside of the optical zone.


In accordance with a seventh aspect, the facing surfaces of the centration member and the haptic system each comprise one of a complementary and interlocking pair, the interlocking pair being disposed circumferentially around the fixed lens and the power changing lens, respectively.


In accordance with an eighth aspect, the peripheral engaging edge is thicker than the circumferential distal edge.


In accordance with a ninth aspect, the thickness ratio of the circumferential distal edge to the peripheral engaging edge is in the range of about 1:5 to about 1:2.


In accordance with a tenth aspect, the primary lens assembly has a higher Young's modulus of elasticity than the power changing lens.


In accordance with an eleventh aspect, at least one of the centration member and the haptic system comprises a plurality of openings.


In accordance with a twelfth aspect, the power changing lens is comprised of two opposing surfaces which are displaced away from each other upon the application of a radial force along a peripheral edge, the two opposing surfaces having central and peripheral regions and a gradually increasing thickness profile from the peripheral to the central regions.


In another embodiment, a two-part accommodating intraocular lens (IOL) device for implantation in a capsular bag of a patient's eye is described. The IOL comprises a primary lens assembly and a power changing lens assembly. The primary lens assembly comprises a fixed lens and a centration member disposed peripherally of the fixed lens. The centration member has a radially-compressible peripheral edge having an outer circumferential surface configured to engage the capsular bag of the patient's eye and an inner circumferential surface spaced radially inward of the outer circumferential surface. The power changing lens comprises an enclosed and fluid- or gel-filled lens cavity and a haptic system disposed peripherally of the lens cavity. The haptic system has a circumferential edge configured to engage the inner circumferential surface. Radial compression applied to the outer circumferential surface causes at least one of an increase in curvature and a decrease in diameter of the lens cavity and radial compression applied to the outer circumferential surface does not cause an increase in curvature or a decrease in diameter of the fixed lens.


In accordance with a first aspect, the centration member further comprises circumferential hinges between the fixed lens and the peripheral edge, the circumferential hinges being disposed on opposing sides of the centration member.


In accordance with a second aspect, the centration member further comprises a single circumferential hinge between the fixed lens and the peripheral edge.


In accordance with a third aspect, the circumferential hinge is disposed on an inner surface of the haptic facing the power changing lens.


In accordance with a fourth aspect, the circumferential edge of the haptic system and the inner circumferential surface of the peripheral edge have complementary rounded surfaces and radial compression applied to the outer circumferential surface cause the peripheral edge to tilt radially inwardly about the circumferential hinge.


In accordance with a fifth aspect, the power changing lens is entirely contained within the peripheral edge of the primary lens assembly.


In accordance with a sixth aspect, the power changing lens further comprises a circumferential lip disposed radially inwardly of the inner surface of the circumferential edge.


In accordance with an seventh aspect, the power changing lens is comprised of two opposing surfaces which are displaced away from each other upon the application of a radial force along a peripheral edge, the two opposing surfaces having central and peripheral regions, wherein the region has a thickness that is at least two times, preferably at least three times, and most preferably at least 4 times greater than a thickness of the peripheral region.


In a further embodiment, a method for implanting a two-part IOL device in a capsular bag of a patient's eye is described. The method comprises first inserting and positioning a primary lens assembly in the capsular bag of the patient's eye through an incision located in the cornea, the primary lens having a fixed lens and a centration member disposed peripherally of the fixed lens. The next step comprises inserting and positioning a power changing lens in the capsular bag of the patient's eye anteriorly of the primary lens assembly, the power changing lens comprising an enclosed and fluid- or gel-filled lens cavity and a haptic system disposed peripherally of the lens cavity, the haptic system having a peripheral engaging edge configured to contact the capsular bag. The primary lens assembly is in contact with a posterior portion of the capsular bag and the power changing lens is in contact with the anterior portion of the capsular bag after implantation. The fixed lens and the lens cavity are centered about an optical axis.


In accordance with a first aspect, the incision is less than 5 mm, preferably less than 4 mm, and most preferably less than 3 mm.


In accordance with a second aspect, both of the inserting steps are performed through the incision.


In accordance with a third aspect, the method further comprises injecting a viscoelastic material before the inserting and positioning of the power changing lens.


Other objects, features and advantages of the described preferred embodiments will become apparent to those skilled in the art from the following detailed description. It is to be understood, however, that the detailed description and specific examples, while indicating preferred embodiments of the present invention, are given by way of illustration and not limitation. Many changes and modifications within the scope of the present invention may be made without departing from the spirit thereof, and the invention includes all such modifications.





BRIEF DESCRIPTION OF THE DRAWINGS

Illustrative embodiments of the present disclosure are described herein with reference to the accompanying drawings, in which:



FIG. 1 is an exploded perspective view of an embodiment of the two-part accommodating IOL.



FIG. 2 is an exploded side cross-sectional view of the two-part accommodating IOL of FIG. 1.



FIG. 3 is an assembled side view of the two-part accommodating IOL of FIG. 1, in which the power changing lens and the primary lens are in sliding contact with one another.



FIG. 4A through 4F are a cross-sectional view of various embodiments of the two-part accommodating IOL.



FIG. 5 is an exploded perspective view of an embodiment of the two-part accommodating IOL.



FIGS. 6A and 6B are a top and side plan views of the power-changing lens of the two-part IOL of FIG. 5.



FIGS. 7A and 7B are top and side plan views of the primary lens of the two-part IOL of FIG. 5.



FIGS. 8A and 8B are exploded and coupled cross-sectional views of another embodiment of a two-part accommodating IOL in which the power changing lens and the primary lens are coupled together.



FIGS. 9A and 9B are cross-sectional views of alternate embodiments of a two-part accommodating IOL in which the power changing lens and the primary lens are coupled together.



FIGS. 10A and 10B are exploded and coupled cross-sectional views of a further embodiment of a two-part accommodating IOL in which the power changing lens and the primary lens are coupled together.



FIGS. 11A through 11F are top views of various alternate embodiments of the primary lens.





Like numerals refer to like parts throughout the several views of the drawings.


DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

Specific, non-limiting embodiments of the present invention will now be described with reference to the drawings. It should be understood that such embodiments are by way of example and are merely illustrative of but a small number of embodiments within the scope of the present invention. Various changes and modifications obvious to one skilled in the art to which the present invention pertains are deemed to be within the spirit, scope and contemplation of the present invention as further defined in the appended claims.



FIGS. 1-3 depict an embodiment of a two-part accommodating IOL device 100 in which the power changing lens 110 and the primary lens 120 are in sliding contact with one another.


The power changing lens 110 is depicted as comprising a fluid- or gel-filled lens chamber 112 and a haptic system 114 disposed peripherally of the fluid- or gel-filled lens chamber 112. The haptic system 114 comprises a peripheral engaging edge 116 that is configured to engage the capsular bag of the patient's eye, generally at a location where it is attached via zonules to the ciliary muscles. A plurality of through holes 115 may be disposed along the circumference of the haptic system 114 to reduce material bulk and thus the delivery profile of the power changing lens 110.


The primary lens 120 is depicted as comprising a fixed-power lens 122 and a plurality of centration members 124 disposed symmetrically about the fixed-power lens. The centration member 124 comprises a distal edge 126 and through holes 125 to reduce the resistance to radial compression exerted by the capsular bag.


The presence of the holes 115 in the power lens 110 allows the manipulation of both the power lens 110 and the primary lens 120 underneath it. The holes 115 also help reduce the delivery profile of the power lens 110 and permits both the power lens 110 and the primary lens 120 to be manipulated to center it in the capsular bag during implantation. The presence of holes 115 may also reduce the rigidity of the power lens. Similarly, the primary lens 120 also has holes 125 that permit manipulation and reduce delivery profile. The holes 125 of the primary lens 120 are additionally shaped so as to reduce the likelihood of grabbing the power changing lens 110 when the power changing lens 110 is implanted into the capsular bag of the patient's eye after the primary lens 120 has already been implanted.


The power changing lens 110 and the primary lens 120 is configured to be in sliding contact with one another, while maintaining a separation between the fluid- or gel-filled lens chamber 112 and the fixed-power lens 122. In one embodiment, this distance is maintained by angling either one or both of the haptic system 114 and the centration member 124 towards one another. As shown in FIGS. 2 and 3, the sliding contact between the power changing lens 110 and the primary lens 120 is made at the first and second coupling surfaces 118, 128, respectively.


The power changing lens 110 is sized and shaped to take on and respond to the radially-inward forces which are applied along the peripheral edge 116 of the lens 110. In contrast, the primary lens 120 does not participate in providing an accommodative response and thus is sized and shaped so as to avoid interfering or resisting the radial compressive forces that are applied to the power changing lens 110. This may be accomplished by controlling the relative diameters and thicknesses of the power changing lens 110 and the primary lens 120 to maximize the extent to which the radial compressive forces are applied onto the power changing lens 110 and to minimize the extent to which these forces are applied onto the primary lens 120.


In a preferred embodiment, as depicted in FIG. 2, the thickness t1 of peripheral engaging edge 116 of the power changing lens 110 is substantially thicker than the thickness t2 of the distal edge 126 of the fixed-power lens 122. In a preferred embodiment, the thickness ratio of t1 to t2 is 2:1, preferably 3:1, more preferably 4:1 and most preferably 5:1. In another preferred embodiment, as depicted in FIG. 3, the diameter d1 of the power changing lens 110 is greater than the diameter d2 of the primary lens 120.


In one preferred embodiment, at least the opposing sides or walls of the lens chamber 112 is made of a material of sufficient mechanical strength to withstand physical manipulation during implantation, but is of sufficiently low Young's modulus so as to minimize its resistance to deformation. In a preferred embodiment, the opposing sides of the lens chamber 112 is made of a polymer having a Young's modulus of 100 psi or less, preferably 75 psi or less, and most preferably 50 psi or less. In one preferred embodiment, the remaining portions of the IOL 100 has a Young's modulus that is greater than the Young's modulus of the lens chamber 112. The walls of the lens chamber 112 may be a polymer, preferably a silicone polymer and more preferably a phenyl siloxane, such as a vinyl-terminated phenyl siloxane or a vinyl-terminated diphenyl siloxane. In order to impart sufficient mechanical strength, the polymer may be crosslinked, reinforced with fillers, or both. The fillers may be a resin or silica that have been functionalized to react with the polymer.


The walls of the lens chamber 112 define an enclosed cavity that is filled with a fluid or gel having specific physical and chemical characteristics to enhance the range of refractive power provided by the IOL during accommodation. The fluid or gel is selected such that it cooperates with the power changing lens 110 in providing a sufficient range of accommodation of up to at least 3 diopters, preferably up to at least 5 diopters, preferably up to at least 10 diopters and most preferably up to at least 15 diopters. In a preferred embodiment, the enclosed cavity is filled with the fluid or gel before implantation of the IOL 100 into the capsular bag 40 of the eye and, in a more preferred embodiment, the cavity is filled with the fluid or gel in the manufacture of the IOL 100.



FIGS. 4A-4F and 8-10 more clearly depict the location of the fluid or gel (213, 313, 413, 513) contained within the power changing lens (210, 310, 410, 510). In one preferred embodiment the enclosed cavity defined by the walls of the lens chamber 112 is filled with a fluid, such as a gas or a liquid, having low viscosity at room temperature and a high refractive index. In a preferred embodiment, the fluid (213, 313, 413, 513) is a liquid having a viscosity of 1,000 cP or less at 23° C. and a refractive index of at least 1.46, 1.47, 1.48, or 1.49. The fluid may be a polymer, preferably a silicone polymer, and more preferably a phenyl siloxane polymer, such as a vinyl-terminated phenyl siloxane polymer or a vinyl-terminated diphenyl siloxane polymer. Preferably in embodiments where the fluid is made of a polymer, the polymer is preferably not crosslinked and the polymer may be linear or branched. Where the fluid is a vinyl-terminated phenyl siloxane polymer or diphenyl siloxane polymer, the vinyl groups may be reacted to form other moieties that do not form crosslinkages.


In accordance with one embodiment, fluid (213, 313, 413, 513) may be a polyphenyl ether (“PPE”), as described in U.S. Pat. No. 7,256,943, entitled “Variable Focus Liquid-Filled Lens Using Polyphenyl Ethers” to Teledyne Licensing, LLC, the entire contents of which are incorporated herein by reference as if set forth fully herein.


In accordance with another embodiment, the fluid (213, 313, 413, 513) may be a fluorinated polyphenyl ether (“FPPE”). FPPE has the unique advantage of providing tunability of the refractive index while being a chemically inert, biocompatible fluid with dispersion properties. The tunability is provided by the increasing or decreasing the phenyl and fluoro content of the polymer. Increasing the phenyl content will effectively increase the refractive index of the FPPE, whereas increasing the fluoro content will decrease the refractive index of the FPPE while decreasing the permeability of the FPPE fluid through the walls of the lens chamber 112.


In another preferred embodiment, the enclosed cavity defined by walls of the lens chamber 112 is filled with a gel (213, 313, 413, 513). The gel (213, 313, 413, 513) preferably has a refractive index of at least 1.46, 1.47, 1.48, or 1.49. The gel may also preferably have a Young's modulus of 20 psi or less, 10 psi or less, 4 psi or less, 1 psi or less, 0.5 psi or less, 0.25 psi or less and 0.01 psi or less. In a preferred embodiment, the gel (213, 313, 413, 513) is a crosslinked polymer, preferably a crosslinked silicone polymer, and more preferably a crosslinked phenyl siloxane polymer, such as a vinyl-terminated phenyl siloxane polymer or a vinyl-terminated diphenyl siloxane polymer. Other optically clear polymer liquids or gels, in addition to siloxane polymers, may be used to fill the enclosed cavity and such polymers may be branched, unbranched, crosslinked or uncrosslinked or any combination of the foregoing.


A gel has the advantages of being extended in molecular weight from being crosslinked, more self-adherent and also adherent to the walls or opposing sides lens chamber 112 than most liquids. This makes a gel less likely to leak through the walls of the power changing lens. In order to obtain the combination of accommodative power with relatively small deformations in the curvature of the power changing lens, the gel (213, 313, 413, 513) is selected so as to have a high refractive index while being made of an optically clear material that is characterized as having a low Young's modulus. Thus, in a preferred embodiment, the gel has a refractive index of 1.46 or greater, preferably 1.47 or greater, 1.48 or greater and most preferably 1.49 or greater. At the same time, the gel preferably has a Young's modulus of 10 psi or less, preferably 5 psi or less, and more preferably 1 psi or less. In a particularly preferred embodiment, the gel has a Young's modulus of 0.5 psi or less, preferably 0.25 psi or less, and most preferably 0.01 psi or less. It is understood that at lower Young's modulus, the gel will present less resistance to deformation and thus the greater the deformation of the power changing lens 110 for a given unit of applied force.


In particularly preferred embodiment, the gel is a vinyl-terminated phenyl siloxane that is produced based on one of the four formulas provided as follows:


Formula 1:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.35 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0033 psi


Formula 2:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.4 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0086 psi


Formula 3:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.5 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=0.0840 psi


Formula 4:

    • 100 parts 20-25 mole % vinyl terminated diphenylsiloxane-dimethylsiloxane copolymer (Gelest PDV 2335).
    • 3 ppm platinum complex catalyst
    • 0.6 pph of phenyl siloxane hydride crosslinker (Nusil XL-106)
    • Young's modulus of elasticity=2.6 psi


The walls of the lens chamber and the fluid or gel contained within the cavity is preferably selected so as to prevent or reduce the likelihood of the fluid or gel migrating outside of the lens chamber. Thus, in a preferred embodiment, one or both of the power changing lens and the fluid or gel (213, 313, 413, 513) is/are selected from biocompatible materials that optimize the resistance to permeability of the fluid or gel across the power changing lens.


One method of decreasing the permeability of the gel contained inside the cavity and across the power changing lens is to provide a gel that is cross-linked. The degree of cross-linking, however, must be selected and controlled such that, on the one hand, the power changing lens and the gel have a sufficiently low Young's modulus to minimize the resistance of the power changing lens to deformation and, on the other hand, to minimize the permeation of the gel across the power changing lens. Thus, in a preferred embodiment, longer chain polymers that are lightly cross-linked, such as those used for silicone gels, starting with monomers having molecular weights that are greater than 35,000 daltons, preferably greater than 50,000 daltons and, most preferably, at least 70,000 daltons are desired.


In another preferred embodiment, a gel is used having low permeability extractables. Such gels may be formulated by using long chain polymers that are branched.


In a preferred embodiment, one or both of the lens chamber walls and the gel may be made of homo- or co-polymers of phenyl-substituted silicones.


For the lens chamber walls, the crosslinked homo- or co-polymers preferably have a diphenyl content of 5-25 mol %, preferably 10-20 mol % and more preferably 15-18 mol %. Alternatively, for the lens chamber walls, the homo- or co-polymers preferably have a phenyl content of 10-50 mol %, preferably 20-40 mol %, and more preferably 30-36 mol %.


For the gel, the homo- or co-polymers preferably have a diphenyl content of 10-35 mol %, preferably 15-30 mol % and more preferably 20-25 mol %. Alternatively, for the gel, the homo- or co-polymers preferably have a phenyl content of 20-70 mol %, preferably 30-60 mol % and more preferably 40-50 mol %.


In a particularly preferred embodiment, the walls of the lens chamber are made of a crosslinked phenyl siloxane having a diphenyl content of about 15-18 mol % or a phenyl content of about 30-36 mol % and the gel is made of a phenyl siloxane having a diphenyl content of about 20-25 mol % or a phenyl content of about 40-50 mol %. The walls of the lens chamber walls are understood to be more crosslinked than the gel.


In a particularly preferred embodiment, the lens chamber walls are made of a vinyl-terminated phenyl siloxane, most preferably a crosslinked vinyl-terminated phenyl siloxane. Reinforcing agents, such as silica, may also be included in a range of 10-70 mol %, preferably 20-60 mol % and most preferably 30-50 mol %.


The walls of the lens chamber and the fluid or gel contained within the cavity is also preferably selected so as to increase the range of accommodative power that is provided by the lens chamber. In one preferred embodiment, the walls of the lens chamber are made of a material having a lower refractive index than the fluid or gel contained in the enclosed cavity. In one preferred embodiment, the refractive index of the walls of the lens chamber is 1.38 and the refractive index of the gel or fluid contained therein is 1.49.


The differential refractive indices provided by the lens chamber walls and the gel or liquid contained within the lens chamber may be provided by differences in the materials or the composition of the materials used for the lens chamber walls and the gel or liquid.


In one embodiment, both the lens chamber walls and the gel or liquid is made of a phenyl siloxane having different diphenyl or phenyl content. In a preferred embodiment, the lens chamber walls have a diphenyl or phenyl content that is less than that for the gel or liquid. In another preferred embodiment, the walls of the lens chamber may be made of a cross-linked vinyl-terminated phenyl siloxane having a diphenyl content of about 15-18 mol % or a phenyl content of about 30-36 mol % and the gel contained within the lens chamber walls may be made of a vinyl-terminated phenyl-siloxane having a diphenyl content of 20-25 mol % or a phenyl content of 30-36 mol %.


In another embodiment, the differential refractive indices may be provided by providing a dimethyl siloxane for the lens chamber walls and the gel may be a phenyl siloxane having a high diphenyl or phenyl content. In a preferred embodiment, the diphenyl content is at last 20 mol %, at least 25 mol %, at least 30 mol %, at least 35 mol %, and at least 40 mol %. Alternatively, the phenyl content is at least 40 mol %, at least 50 mol %, at least 60 mol %, at least 70 mol % and at least 80 mol %.


In a further embodiment, the differential refractive indices may be provided by a crosslinked fluoro siloxane, such as a 3,3,3-trifluoropropylmethyl siloxane and the gel may be a phenyl siloxane having a high diphenyl or phenyl content. In a preferred embodiment, the diphenyl content is at least 20 mol %, at least 25 mol %, at least 30 mol %, at least 35 mol %, and at least 40 mol %. Alternatively, the phenyl content is at least 40 mol %, at least 50 mol %, at least 60 mol %, at least 70 mol %, and at least 80 mol %.



FIGS. 4A-4F depict alternate embodiments of the two-part IOL device 200A-F in which the shape and configuration of the power changing lens 210 and the primary lens 230 are varied.


In each of these embodiments, certain features remain the same. The power changing lens 210 is depicted as comprising a fluid- or gel-filled lens chamber 212 and a haptic system 214 disposed peripherally of the fluid- or gel-filled lens chamber 212. The lens chamber 212 comprises two opposing surfaces which are divided into a central regions 212a, 212b about the central axis A-A (See FIG. 1) and peripheral regions 211a, 211b. In a preferred embodiment, the central regions 212a, 212b have a gradually increasing thickness radially towards the center of the lens chamber 212 from the peripheral regions 211a, 211b.


In a preferred embodiment, the center point of the central regions 212a, 212b has a thickness that is two times or more, preferably three times or more, and most preferably 4 times or more than the thickness of the peripheral region 211a, 211b. A fluid or gel 213 is contained between the opposing surfaces. In another preferred embodiment, the point of greatest thickness in the central region 212a, 212b and the point of least thickness in the peripheral region 211a, 211b is a ratio of 2:1 or greater, preferably 3:1 or greater, and most preferably 4:1 or greater. In a preferred embodiment, the thickness at the optical axis or the center of the central region 212a, 212b is about 200 microns and the thickness at the peripheral region 211a, 211b is about 50 microns. The increased thickness in the central region 212a, 212b is provided so as to prevent the opposing surfaces of the lens chamber 212 from buckling when it is deformed in response to accommodation. It is understood that in the various embodiments of the power lens depicted in the figures, the opposing sides preferably has the thickness profiles as described herein and depicted in FIGS. 4A-4F. References to the optical axis or optical axis A-A made herein is understood to mean the line bisecting the center of the IOL device, as shown in FIG. 1.


The opposing surfaces of the lens chamber 212 actuate towards and away from each other when the eye is unaccommodated and accommodated, respectively. The haptic system 214 comprises a peripheral engaging edge 216 and a first coupling surface 218 adjacent the peripheral engaging edge 216. The primary lens assembly 230 comprises a fixed lens 232 and a plurality of centration members 224 disposed about the fixed lens 232. The centration members 224 comprise a distal edge 236 and a second contacting surfaces 238 in sliding contact with the first contacting surfaces 218 of the power changing lens 210.


In a preferred embodiment, the primary lens 230 is substantially thicker than one of the opposing sides lens chamber 212, as measured along the optical axis A-A. In a preferred embodiment, the thickness of each one of the opposing sides lens chamber 212, as along the optical axis A-A is less than ½, preferably less than ⅓, preferably less than ¼, and most preferably less than ⅕ of the thickness of the primary lens 230 at the central optical axis A-A. Because the primary lens 230 is substantially thicker than either one of the opposing sides lens chamber 212, the primary lens 230 has an effective Young's modulus that is substantially greater than either one of the opposing sides of the chamber 212.


Turning now to the various distinguishing features of the two-part IOL devices, reference is made with respect to FIG. 4A of the IOL device 200A in which the primary lens 230 is depicted as comprising a hinge 240 and angled or squared edge 239. The hinge 240 is provided on the centration members 224 to permit it to bend axially, compress radially, or both in response the accommodative forces exerted on the capsular bag. The hinge 240 therefore permits these accommodative forces to act upon the peripheral engaging edge 216 of the power changing lens 210 to actuate the opposing surfaces 212a, 212b away from or towards one another. The squared edge 239 is provided to help fix the primary lens assembly to the capsular bag and also to reduce the likelihood of posterior capsular opacification (PCO) from occurring.



FIG. 4B depicts an IOL device 200B that is similar in many respects with FIG. 4A with the exception that the hinge 242 disposed on the centration members 224 is substantially wider so as to provide less resistance to bending, compression or both in response to the accommodative forces exerted on the capsular bag and thus onto the distal edge 236 of the centration member 224. It is understood that for both IOL devices 200A, 200B, the hinge 240 is provided on the surface facing away from the power changing lens 210 and therefore the distal edge 236 pivot in a direction away from the power changing lens 210 when a radially compressive force is applied to the distal edge 236.



FIG. 4C depicts an IOL device 200C in which the primary lens assembly 230 comprises only a squared edge 239 around the periphery of the fixed lens 232. Because the primary lens assembly 230 does not include a hinge, it is expected that this IOL device 200C will be significantly more rigid than the IOL devices 200A and 200B depicted in FIGS. 4A and 4B, respectively.



FIG. 4D depicts an IOL device 200D in which is similar to the IOL device 200B of FIG. 4B with the exception that the hinge 244 is now located on the surface facing the power changing lens 210. Thus, the distal edge 236 will pivot in a direction toward the power changing lens 210 when a radially compressive force is applied to the distal edge 236.



FIG. 4E depicts an IOL device 200E having a greater degree of engagement between the power changing lens 210 and the fixed lens assembly 230. The power changing lens 210 and the fixed lens assembly 230 comprise complementary and interlocking hooks 250, 260 disposed peripherally of the fluid- or gel-filled lens chamber 212 and the fixed lens 232, respectively. Unlike the IOL devices depicted in FIGS. 4A-4D, the power changing lens 210 and the fixed lens assembly 230 are coupled to one another by engagement of the interlocking hooks 250, 260.



FIG. 4F depicts an IOL device 200F in which the power changing lens 210 comprises a circumferential projection 246 downwardly of the peripheral engaging edge 216 to constrain the movement of the fixed lens assembly 230 within the boundary defined by the circumferential portion 246. As a result, it is understood that the fixed lens assembly 230 has a diameter that is less than the diameter defined by the circumferential projection 246.



FIGS. 5-8 depict another embodiment of a two-part IOL device 300 in which the power changing lens 310 is constrained within the boundaries of the fixed lens assembly 350. As shown in FIGS. 5-6, the power changing lens 310 has a roughly disc-shaped outer surface and comprises an enclosed fluid- or gel-filled lens 312, a haptic system 314 and a circumferential peripheral engaging edge 316. The power changing lens 310 further comprises a plurality of circumferential holes 315 disposed peripherally of the enclosed fluid- or gel-filled lens 312. The fluid- or gel-filled lens 312 comprises two opposing surfaces which are divided into central regions 312a, 312b and peripheral regions 311a, 311b. In a preferred embodiment, the central regions 312a, 312b have a gradually increasing thickness radially towards the center of the fluid- or gel-filled lens 312 from the peripheral regions 311a, 311b. In a preferred embodiment, the center point of the central regions 312a, 312b has a thickness that is two times or more, preferably three times or more, and most preferably 4 times or more than the thickness of the peripheral region 311a, 311b. A fluid or gel 313 is contained between the opposing surfaces. In another preferred embodiment, the point of greatest thickness in the central region 312a, 312b and the point of least thickness in the peripheral region 311a, 311b is a ratio of 2:1 or greater, preferably 3:1 or greater, and most preferably 4:1 or greater. In a preferred embodiment, the thickness at the optical axis or the center of the central region 312a, 312b is about 200 microns and the thickness at the peripheral region 311a, 311b is about 50 microns. The increased thickness in the central region 312a, 312b is provided so as to prevent the opposing surfaces of the fluid- or gel-filled lens 312 from buckling when it is deformed in response to accommodation.


The fixed lens assembly 350 is configured to house and receive the power changing lens 310. The fixed lens assembly 350 comprises a fixed lens 352 centrally disposed and an internal cavity defined by the fixed lens 352, the peripheral side wall 356 and a plurality of radial protrusions 358 projecting inwardly from the top of the peripheral side wall 356. Circumferential grooves or hinges 354 surround the fixed lens 352 and permit pivoting or compression of the peripheral side wall 356 radially inward. A plurality of circumferential holes 359 are provided about the periphery of the fixed lens 352 to permit the flow of aqueous fluid therethrough and into the cavity 375 (FIG. 8B) defined between the power changing lens 310 and the fixed lens assembly 350. The holes 359 also to reduce the material bulk and thus the delivery profile of the fixed lens assembly 350. As shown in FIG. 8B, a space 375 is defined between the power changing lens 310 and the fixed lens assembly 350.


The implantation and assembly of the two-part IOL device 300 follows two steps. In a first step, the fixed lens assembly 350 is inserted into the capsular bag of the eye following capsulhorexis. The fixed lens assembly 350 is centered such that the peripheral side wall 356 engages the circumferential area of the capsular bag that is most densely connected to the zonules and the fixed lens 352 is centered about the optical axis and is in contact with the posterior portion of the capsular bag. In a second step, the power changing lens 310 is inserted into the capsular bag and positioned within the cavity 375 of the fixed lens assembly 350 such that the peripheral engaging edge 316 is in proximity to or in contact with the inner surface 360 of the peripheral side wall 356. Thus, radial compression applied to the peripheral side wall 356 is transmitted to the peripheral engaging edge 316 of the power changing lens 310 such that the fluid- or gel-filled lens increases and decreases in curvature to provide an accommodating response to the relaxation and contraction of the ciliary muscles of the eye, respectively.



FIGS. 9-10 are cross-sectional views of various embodiments of the two-part IOL device.



FIGS. 9A and 9B are cross-sectional view of two alternate embodiments of the two-part IOL device 400A, 400B. In both embodiments, the two-part IOL device comprises a power changing lens 410 and a fixed lens assembly 450. The power changing lens 410 comprises a fluid- or gel-filled lens chamber 412 defined by opposing surfaces and a fluid or gel 413 contained therein. A haptic 414 having an engaging edge 416 is provided peripherally of the lens chamber 412. The fixed lens assembly 450 comprises a centrally-disposed fixed lens 452 and a hinge 454 disposed peripherally of the lens 452. The hinge 454 is preferably disposed on the surface of the fixed-lens assembly 450 facing the power changing lens 410 such that radial compressive forces applied to the circumferential periphery 456 causes it to pivot towards the power changing lens 410 and thus transmit the radially-compressive forces onto the engaging edge 416 of the fluid- or gel-filled lens 412 to effectuate a curvature change in the opposing sides of the fluid- or gel-filled lens chamber 412. The difference between the IOL devices 400A and 400B is that the engaging edge 416 in 400A is in spaced relation to the inner surface 460 of the circumferential periphery 456, whereas the engaging edge 416 in 400B is in contact with the inner surface 460 of the circumferential periphery 456 in the absence of a radially-applied force.


Additionally the IOL devices 400A, 400B are provided with curved surfaces at the points of contact between the power changing lens 410 and the fixed lens assembly 450 to facilitate a sliding movement between them. Thus, in a preferred embodiment, at least the circumferential periphery 456, the engaging edge 416 and the inner surface 460 of the circumferential periphery 456 are curved surfaces.



FIGS. 10A and 10B depict yet another embodiment of the two-part IOL device 500 comprising a power changing lens 510 and a fixed lens assembly 550. The power changing lens 510 comprises a enclosed lens chamber 512 defined by two opposing sides which change in curvature in response to radial forces applied to the periphery 516 of the haptic 514.


The two opposing surfaces are divided into central regions 512a, 512b and peripheral regions 511a, 511b. In a preferred embodiment, the central regions 512a, 512b have a gradually increasing thickness radially towards the center of the enclosed lens chamber 512 from the peripheral regions 511a, 511b. In a preferred embodiment, the center point of the central regions 512a, 512b has a thickness that is two times or more, preferably three times or more, and most preferably 4 times or more than the thickness of the peripheral region 511a, 511b. A fluid or gel 213 is contained between the opposing surfaces. In another preferred embodiment, the point of greatest thickness in the central region 512a, 512b and the point of least thickness in the peripheral region 511a, 511b is a ratio of 2:1 or greater, preferably 3:1 or greater, and most preferably 4:1 or greater. In a preferred embodiment, the thickness at the optical axis or the center of the central region 512a, 512b is about 200 microns and the thickness at the peripheral region 511a, 511b is about 50 microns. The increased thickness in the central region 512a, 512b is provided so as to prevent the opposing surfaces of the enclosed lens chamber 512 from buckling when it is deformed in response to accommodation. It is understood that in the various embodiments of the power lens depicted in the figures, the opposing sides preferably has the thickness profiles as described herein and depicted in FIGS. 4A-4F.


The fixed-lens assembly 550 comprises a fixed lens 552 that does not change in shape or curvature. An internal cavity is defined by the fixed lens 552 and the circumferential side walls 560. A circumferential hinge 554 provided on the fixed-lens assembly 550 peripherally of the fixed lens 552. The hinge 554 is disposed around the fixed lens 554 and thus permits the peripheral side wall 556 to be compressed radially-inwards in the direction of the arrows B to compress the power changing lens 510 at the contacting periphery 516. This, in turn, causes the opposing sides 512a, 512b to curve away from one another. Once the radial forces are no longer applied, the fixed lens assembly is resiliently biased to the expanded and unaccommodated state and the peripheral side wall expands in the direction as indicated by the arrows A.



FIGS. 11A-11F depict various alternative embodiments of the fixed lens assemblies 600A-F that may be used in connection with any one of the fixed lens assembly described herein to form a two-part IOL device of the type described in FIGS. 1-3. As depicted in each of FIGS. 11A-11F, the haptics 614A-F are disposed in a symmetric matter so as to ensure centration of the power changing lens. FIG. 11A depicts a fixed lens assembly 600A having a lens 612A surrounded by four symmetrically disposed tabs 614A. The tabs each comprise an aperture 615A and an engaging edge 616A configured to engage the capsular bag of the patient's eye. FIG. 11B depict a similar arrangement of four haptics 614B, except that the haptics each have a rounded edge 616B and haptic pairs are pointed towards one another. FIG. 11C depict an arrangement of four haptics 614C, also having rounded edges 616C with the haptics being pointed in the same direction.



FIG. 11D depicts a fixed lens assembly 600D comprising a lens 612D and a plurality of haptics 614D each with an aperture 615D disposed therethrough. The haptics 614D further comprise a sizing finger 620 projecting from the outer engaging edge 616D. Implantation of the two-part IOL device typically requires the implantation of the fixed lens assembly first. Once the fixed lens assembly is implanted and positioned, the lens capsule walls may compress the engaging edge 616D and displace the sizing finger 620 toward the lens 612D. The extent to which the sizing finger 620 is displaced toward the lens 612D provides an indication as to the size of the patient's lens capsule so as to permit selection of the appropriately-sized power changing lens that is to be subsequently implanted in the patient's lens capsule.



FIG. 11E depicts yet another fixed lens assembly 600E comprising four haptic tabs 614E each comprising a triangular shaped aperture 615E and a peripheral engaging edge 616E. The significance of the triangular shaped aperture 615E is to reduce the risk of snagging portions of the power changing lens during implantation.



FIG. 11F depicts a further embodiment of the fixed lens assembly 600F comprising a lens 612F and three plate haptics 614F projecting therefrom. Because the configuration of the plate haptics 614F provides for a stiffer haptic, the fixed lens assembly 600F is preferably undersized relative to the lens capsule.


The invention described and claimed herein is not to be limited in scope by the specific preferred embodiments disclosed herein, as these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

Claims
  • 1. A two-part accommodating intraocular lens (IOL) device comprising: a power changing lens comprising an anterior surface, a posterior surface, an enclosed and fluid- or gel-filled lens cavity disposed between the anterior surface and the posterior surface, and a peripheral body disposed peripherally of the enclosed and fluid- or gel-filled lens cavity; anda base assembly comprising an optic centered on an optical axis and a haptic disposed peripherally of the optic, the haptic comprising: an inner circumferential surface engaging a circumferential edge of the peripheral body of the power changing lens; anda radially-compressible outer circumference spaced radially outward of the inner circumferential surface and configured to engage a capsular bag of a patient's eye, wherein the radially-compressible outer circumference surrounds the power changing lens and is uniformly radially compressible in response to ocular forces;wherein radial forces exerted on the radially-compressible outer circumference of the haptic are transmitted radially inward to the peripheral body of the power changing lens to cause an increase in curvature of at least one of the anterior and the posterior surfaces of the power changing lens.
  • 2. The two-part accommodating IOL device of claim 1, wherein the anterior and the posterior surfaces of the power changing lens are spaced away from each other.
  • 3. The two-part accommodating IOL device of claim 2, wherein an anterior surface of the optic is spaced away from the posterior surface of the power changing lens.
  • 4. The two-part accommodating IOL device of claim 3, wherein the increase in curvature of the at least one of the anterior and the posterior surfaces occurs without contact between the optic and the posterior surface of the power changing lens.
  • 5. The two-part accommodating IOL device of claim 4, wherein the increase in curvature of the at least one of the anterior and the posterior surfaces occurs without contact between the anterior and the posterior surfaces of the power changing lens.
  • 6. The two-part accommodating IOL device of claim 3, further comprising a second cavity spacing apart the optic and the posterior surface of the power changing lens.
  • 7. The two-part accommodating IOL device of claim 6, wherein the enclosed and fluid- or gel-filled lens cavity and the second cavity are not in fluid communication with the haptic.
  • 8. The two-part accommodating IOL device of claim 6, wherein the second cavity is configured to permit a flow of aqueous fluid therein when the two-part accommodating IOL device is disposed in the patient's eye.
  • 9. The two-part accommodating IOL device of claim 6, further comprising a plurality of holes around a periphery of the optic, the plurality of holes configured to permit a flow of aqueous body fluid into the second cavity.
  • 10. The two-part accommodating IOL device of claim 1, wherein each of the anterior surface and the posterior surface of the enclosed and fluid-or gel-filled lens cavity comprises a central region centered on the optical axis and a peripheral region disposed peripherally of the central region.
  • 11. The two-part accommodating IOL device of claim 10, wherein a thickness of the central region of the at least one of the anterior surface and the posterior surface of the power changing lens is at least two times greater than a thickness of the peripheral region of the at least one of the anterior surface and the posterior surface of the power changing lens.
  • 12. The two-part accommodating IOL device of claim 10, wherein a thickness of the central region of the at least one of the anterior surface and the posterior surface of the power changing lens is at least three times greater than a thickness of the peripheral region of the at least one of the anterior surface and the posterior surface of the power changing lens.
  • 13. The two-part accommodating IOL device of claim 10, wherein a thickness of the central region of the at least one of the anterior surface and the posterior surface of the power changing lens is at least four times greater than a thickness of the peripheral region of the at least one of the anterior surface and the posterior surface of the power changing lens.
  • 14. The two-part accommodating IOL device of claim 1, wherein the base assembly further comprises a plurality of radial protrusions disposed over an anterior side of the peripheral body of the power changing lens when the power changing lens is disposed in the base assembly.
  • 15. The two-part accommodating IOL device of claim 1, wherein the haptic further comprises circumferential hinges between the optic and the radially-compressible outer circumference.
  • 16. The two-part accommodating IOL device of claim 1, wherein the power changing lens is entirely contained within the radially-compressible outer circumference of the base assembly.
  • 17. The two-part accommodating IOL device of claim 1, wherein the optic is disposed posteriorly of the haptic.
  • 18. The two-part accommodating IOL device of claim 1, wherein the optic is disposed posteriorly of a posterior side of the haptic.
  • 19. A two-part accommodating intraocular lens (IOL) device comprising: a power changing lens comprising an anterior surface, a posterior surface, an enclosed and fluid- or gel-filled lens cavity disposed between the anterior surface and posterior surface, and a peripheral body disposed peripherally of the enclosed and fluid- or gel-filled lens cavity; anda base assembly comprising an optic intersected by an optical axis and a haptic disposed peripherally of the optic, the haptic comprising: an inner circumferential surface engaging a circumferential edge of the peripheral body of the power changing lens; anda radially-compressible outer circumference spaced radially outward of the inner circumferential surface and configured to engage a capsular bag of a patient's eye, wherein the radially-compressible outer circumference surrounds the power changing lens and is uniformly radially compressible in response to ocular forces;wherein radial forces exerted on the radially-compressible outer circumference of the haptic are transmitted radially inward to the peripheral body of the power changing lens to cause an increase in curvature of the anterior surface of the power changing lens.
  • 20. The two-part accommodating IOL device of claim 19, further comprising a second cavity spacing apart the optic and the posterior surface of the power changing lens, the second cavity configured to permit a flow of aqueous fluid therein when the two-part accommodating IOL device is disposed in the patient's eye.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation of U.S. Ser. No. 16/207,658, filed Dec. 3, 2018, which is a continuation of U.S. Ser. No. 15/144,544, now U.S. Pat. No. 10,159,564, filed May 2, 2016, which is a continuation of International Patent Application No. PCT/US2014/063538 filed Oct. 31, 2014, which claims the benefit of Provisional Patent Application No. 61/899,110 filed Nov. 1, 2013, both of which are incorporated herein by reference in their entirety.

US Referenced Citations (591)
Number Name Date Kind
4032502 Lee et al. Jun 1977 A
4073014 Poler Feb 1978 A
4118808 Poler Oct 1978 A
4373218 Schachar Feb 1983 A
4512040 McClure Apr 1985 A
4585457 Kalb Apr 1986 A
4676791 LeMaster et al. Jun 1987 A
4720286 Bailey et al. Jan 1988 A
4731078 Stoy et al. Mar 1988 A
4822360 Deacon Apr 1989 A
4842601 Smith Jun 1989 A
4882368 Elias et al. Nov 1989 A
4888012 Horn et al. Dec 1989 A
4892543 Turley Jan 1990 A
4932966 Christie et al. Jul 1990 A
5035710 Nakada et al. Jul 1991 A
5059668 Fukuda et al. Oct 1991 A
5074876 Kelman Dec 1991 A
5091121 Nakada et al. Feb 1992 A
5152788 Isaacson et al. Oct 1992 A
5167883 Takemasa et al. Dec 1992 A
5171773 Chaffe et al. Dec 1992 A
5227447 Sato et al. Jul 1993 A
5236970 Christ et al. Aug 1993 A
5264522 Mize et al. Nov 1993 A
5275623 Sarfarazi Jan 1994 A
5278258 Gerace et al. Jan 1994 A
5312860 Mize et al. May 1994 A
5326506 Vanderbilt Jul 1994 A
5336487 Refojo et al. Aug 1994 A
5443506 Garabet Aug 1995 A
5447987 Sato et al. Sep 1995 A
5489302 Skottun Feb 1996 A
5583178 Oxman et al. Dec 1996 A
5607472 Thompson Mar 1997 A
5665794 Maxson et al. Sep 1997 A
5854310 Maxson Dec 1998 A
6071439 Bawa et al. Jun 2000 A
6117171 Skottun Sep 2000 A
6197057 Peyman et al. Mar 2001 B1
6200342 Tassignon Mar 2001 B1
6200581 Lin et al. Mar 2001 B1
6201091 Halloran et al. Mar 2001 B1
6361561 Huo et al. Mar 2002 B1
6551354 Ghazizadeh et al. Apr 2003 B1
6616691 Tran Sep 2003 B1
6695881 Peng et al. Feb 2004 B2
6730123 Klopotek May 2004 B1
6797004 Brady et al. Sep 2004 B1
6836374 Esch et al. Dec 2004 B2
6855164 Glazier Feb 2005 B2
6858040 Nguyen et al. Feb 2005 B2
6860601 Shadduck Mar 2005 B2
6881225 Okada Apr 2005 B2
6926736 Peng et al. Aug 2005 B2
6930838 Schachar Aug 2005 B2
6935743 Shadduck Aug 2005 B2
6966649 Shadduck Nov 2005 B2
6969403 Peng et al. Nov 2005 B2
6991651 Portney Jan 2006 B2
7041134 Nguyen et al. May 2006 B2
7063723 Ran Jun 2006 B2
7068439 Esch et al. Jun 2006 B2
7122053 Esch Oct 2006 B2
7150760 Zhang Dec 2006 B2
7217288 Esch et al. May 2007 B2
7220279 Nun May 2007 B2
7223288 Zhang et al. May 2007 B2
7226478 Ting et al. Jun 2007 B2
7229475 Glazier Jun 2007 B2
7238201 Portney et al. Jul 2007 B2
7247168 Esch et al. Jul 2007 B2
7261737 Esch et al. Aug 2007 B2
7264351 Shadduck Sep 2007 B2
7276619 Kunzler et al. Oct 2007 B2
7278739 Shadduck Oct 2007 B2
7316713 Zhang Jan 2008 B2
7416562 Gross Aug 2008 B2
7438723 Esch Oct 2008 B2
7452377 Watling et al. Nov 2008 B2
7453646 Lo Nov 2008 B2
7455691 Feingold et al. Nov 2008 B2
7485144 Esch Feb 2009 B2
7591849 Richardson Sep 2009 B2
7637947 Smith et al. Dec 2009 B2
7662179 Sarfarazi Feb 2010 B2
7675686 Lo et al. Mar 2010 B2
7753953 Yee Jul 2010 B1
7776088 Shadduck Aug 2010 B2
7780729 Nguyen et al. Aug 2010 B2
7815678 Nun Oct 2010 B2
7842087 Nun Nov 2010 B2
7854764 Nun Dec 2010 B2
7857850 Mentak et al. Dec 2010 B2
7918886 Aharoni et al. Apr 2011 B2
7981155 Cumming Jul 2011 B2
7985253 Cumming Jul 2011 B2
7986465 Lo et al. Jul 2011 B1
7998198 Angelopoulos et al. Aug 2011 B2
7998199 Nun Aug 2011 B2
8012204 Weinschenk, III et al. Sep 2011 B2
8018658 Lo Sep 2011 B2
8034106 Mentak et al. Oct 2011 B2
8034107 Stenger Oct 2011 B2
8038711 Clarke Oct 2011 B2
8048155 Shadduck Nov 2011 B2
8052752 Woods et al. Nov 2011 B2
8062361 Nguyen et al. Nov 2011 B2
8066768 Werblin Nov 2011 B2
8066769 Werblin Nov 2011 B2
8070806 Khoury Dec 2011 B2
8158712 Your Apr 2012 B2
8182531 Hermans et al. May 2012 B2
8187325 Zadno-Azizi et al. May 2012 B2
8197541 Schedler Jun 2012 B2
8216306 Coroneo Jul 2012 B2
8246679 Nguyen et al. Aug 2012 B2
8254034 Shields et al. Aug 2012 B1
8257827 Shi et al. Sep 2012 B1
8273123 Nun Sep 2012 B2
8303656 Shadduck Nov 2012 B2
8308800 Chu Nov 2012 B2
8314927 Choi et al. Nov 2012 B2
8320049 Huang et al. Nov 2012 B2
8328869 Smiley et al. Dec 2012 B2
8361145 Scholl et al. Jan 2013 B2
8377124 Hong et al. Feb 2013 B2
8377125 Kellan Feb 2013 B2
8398709 Nun Mar 2013 B2
8414646 De Juan, Jr. et al. Apr 2013 B2
8425597 Glick et al. Apr 2013 B2
8425599 Shadduck Apr 2013 B2
8430928 Liao Apr 2013 B2
8447086 Hildebrand et al. May 2013 B2
8454688 Esch et al. Jun 2013 B2
8475529 Clarke Jul 2013 B2
8491651 Tsai et al. Jul 2013 B2
8496701 Hermans et al. Jul 2013 B2
8500806 Phillips Aug 2013 B1
8518026 Culbertson et al. Aug 2013 B2
8545556 Woods et al. Oct 2013 B2
8579972 Rombach Nov 2013 B2
8585758 Woods Nov 2013 B2
8603167 Rombach Dec 2013 B2
8608799 Blake Dec 2013 B2
8608800 Portney Dec 2013 B2
8613766 Richardson et al. Dec 2013 B2
8647384 Lu Feb 2014 B2
8657810 Culbertson et al. Feb 2014 B2
8657878 Mentak et al. Feb 2014 B2
8668734 Hildebrand et al. Mar 2014 B2
8690942 Hildebrand et al. Mar 2014 B2
8715345 DeBoer et al. May 2014 B2
8715346 De Juan, Jr. et al. May 2014 B2
8734509 Mentak et al. May 2014 B2
8771347 DeBoer et al. Jul 2014 B2
8814934 Geraghty et al. Aug 2014 B2
8834565 Nun Sep 2014 B2
8834566 Jones Sep 2014 B1
8858626 Noy Oct 2014 B2
8867141 Pugh et al. Oct 2014 B2
8900298 Anvar et al. Dec 2014 B2
8900300 Wortz Dec 2014 B1
8920495 Mirlay Dec 2014 B2
8956408 Smiley et al. Feb 2015 B2
8968396 Matthews et al. Mar 2015 B2
8968399 Ghabra Mar 2015 B2
8992609 Shadduck Mar 2015 B2
9005282 Chang et al. Apr 2015 B2
9005283 Nguyen et al. Apr 2015 B2
9034035 Betser et al. May 2015 B2
9044317 Hildebrand et al. Jun 2015 B2
9072600 Tran Jul 2015 B2
9090033 Carson et al. Jul 2015 B2
9095424 Kahook et al. Aug 2015 B2
9125736 Kahook et al. Sep 2015 B2
9149356 Sarfarazi Oct 2015 B2
9186244 Silvestrini et al. Nov 2015 B2
9198752 Woods Dec 2015 B2
9277987 Smiley et al. Mar 2016 B2
9277988 Chu Mar 2016 B1
9289287 Kahook et al. Mar 2016 B2
9326846 Devita Gerardi et al. May 2016 B2
9333072 Ichikawa May 2016 B2
9358103 Wortz et al. Jun 2016 B1
9364316 Kahook et al. Jun 2016 B1
9387069 Kahook et al. Jul 2016 B2
9398949 Werblin Jul 2016 B2
9421088 Kahook et al. Aug 2016 B1
9427312 DeBoer et al. Aug 2016 B2
9433497 DeBoer et al. Sep 2016 B2
9456895 Shadduck Oct 2016 B2
9486311 Argento et al. Nov 2016 B2
9610155 Matthews Apr 2017 B2
9622852 Simonov et al. Apr 2017 B2
9629712 Stenger Apr 2017 B2
9636213 Brady May 2017 B2
9655716 Cumming May 2017 B2
9681946 Kahook et al. Jun 2017 B2
9693858 Hildebrand et al. Jul 2017 B2
9713526 Rombach Jul 2017 B2
9713527 Nishi et al. Jul 2017 B2
9717589 Simonov et al. Aug 2017 B2
9744027 Jansen Aug 2017 B2
9744028 Simonov et al. Aug 2017 B2
9795472 Culbertson et al. Oct 2017 B2
9795473 Smiley et al. Oct 2017 B2
9808339 Dorronsoro Diaz et al. Nov 2017 B2
9814568 Ben Nun Nov 2017 B2
9814570 Robert et al. Nov 2017 B2
9820849 Jansen Nov 2017 B2
9848980 McCafferty Dec 2017 B2
9855137 Smiley et al. Jan 2018 B2
9855139 Matthews et al. Jan 2018 B2
9861469 Simonov et al. Jan 2018 B2
9872762 Scholl et al. Jan 2018 B2
9872763 Smiley et al. Jan 2018 B2
9877825 Kahook et al. Jan 2018 B2
9883940 Nishi et al. Feb 2018 B2
9925039 Sohn et al. Mar 2018 B2
9925040 Kahook et al. Mar 2018 B2
9931202 Borja et al. Apr 2018 B2
9987126 Borja et al. Jun 2018 B2
10004596 Brady et al. Jun 2018 B2
10010405 Hayes Jul 2018 B2
10028824 Kahook et al. Jul 2018 B2
10039635 Wanders Aug 2018 B2
10045844 Smiley et al. Aug 2018 B2
10080648 Kahook et al. Sep 2018 B2
10080649 Zhang et al. Sep 2018 B2
10111745 Silvestrini et al. Oct 2018 B2
10159562 Cady Dec 2018 B2
10159564 Brady et al. Dec 2018 B2
10195017 Culbertson et al. Feb 2019 B2
10195018 Salahieh et al. Feb 2019 B2
10195020 Matthews Feb 2019 B2
10285805 De Juan, Jr. et al. May 2019 B2
10299910 Cady May 2019 B2
10299913 Smiley et al. May 2019 B2
10327886 Sohn et al. Jun 2019 B2
10350056 Argento et al. Jul 2019 B2
10363129 Ghabra et al. Jul 2019 B2
10368979 Scholl et al. Aug 2019 B2
10390937 Smiley et al. Aug 2019 B2
10433949 Smiley et al. Oct 2019 B2
10463473 Rombach et al. Nov 2019 B2
10485654 Brady et al. Nov 2019 B2
10526353 Silvestrini Jan 2020 B2
10548719 Pallikaris et al. Feb 2020 B2
10647831 Silvestrini et al. May 2020 B2
10772721 Rao et al. Sep 2020 B2
10842614 Cady Nov 2020 B2
10842616 Silvestrini et al. Nov 2020 B2
10888219 Smith et al. Jan 2021 B2
10905547 Auld et al. Feb 2021 B2
10912676 Schaller et al. Feb 2021 B2
10917543 Luna et al. Feb 2021 B2
10945832 Cady Mar 2021 B2
10959836 Qureshi et al. Mar 2021 B2
10980629 Anvar et al. Apr 2021 B2
10987183 Brennan et al. Apr 2021 B2
11000363 Campin et al. May 2021 B2
11000367 Wu et al. May 2021 B2
11026838 Raksi Jun 2021 B2
11039901 Tripathi Jun 2021 B2
11040477 Chauvin et al. Jun 2021 B2
11045309 Kahook et al. Jun 2021 B2
11046490 Cerveny Jun 2021 B2
11051884 Tripathi et al. Jul 2021 B2
11065107 Brady et al. Jul 2021 B2
11065109 Argento et al. Jul 2021 B2
11065152 Kelleher et al. Jul 2021 B2
11071449 Heeren Jul 2021 B2
11071622 Matthews Jul 2021 B2
11076948 Kahook et al. Aug 2021 B2
11083567 Honigsbaum Aug 2021 B2
11109957 Cady Sep 2021 B2
11109960 Borja et al. Sep 2021 B2
11110005 Diao et al. Sep 2021 B2
11111055 Reece et al. Sep 2021 B2
11141263 Argento et al. Oct 2021 B2
11162065 Fachin et al. Nov 2021 B2
11166808 Smiley et al. Nov 2021 B2
11166844 Charles Nov 2021 B2
11173008 Mirsepassi et al. Nov 2021 B2
11213606 Jiang et al. Jan 2022 B2
11224540 Sivadas Jan 2022 B2
11298221 McCulloch Apr 2022 B2
20020005344 Heidlas et al. Jan 2002 A1
20020055776 Juan, Jr. et al. May 2002 A1
20020071856 Dillingham et al. Jun 2002 A1
20020120329 Lang et al. Aug 2002 A1
20020138140 Hanna Sep 2002 A1
20030060881 Glick et al. Mar 2003 A1
20030093149 Glazier May 2003 A1
20030105522 Glazier Jun 2003 A1
20030109926 Portney Jun 2003 A1
20030149480 Shadduck Aug 2003 A1
20030158295 Fukuda et al. Aug 2003 A1
20030204254 Peng et al. Oct 2003 A1
20030204256 Peng et al. Oct 2003 A1
20040015236 Sarfarazi Jan 2004 A1
20040082993 Woods Apr 2004 A1
20040082994 Woods et al. Apr 2004 A1
20040111152 Kelman Jun 2004 A1
20040148023 Shu Jul 2004 A1
20040162612 Portney et al. Aug 2004 A1
20040169816 Esch Sep 2004 A1
20040169932 Esch et al. Sep 2004 A1
20040249455 Tran Dec 2004 A1
20050021139 Shadduck Jan 2005 A1
20050071002 Glazier Mar 2005 A1
20050107873 Zhou May 2005 A1
20050119740 Esch et al. Jun 2005 A1
20050137703 Chen Jun 2005 A1
20050149183 Shadduck Jul 2005 A1
20050251253 Gross Nov 2005 A1
20050251254 Brady et al. Nov 2005 A1
20050267575 Nguyen et al. Dec 2005 A1
20060041307 Esch et al. Feb 2006 A1
20060047339 Brown Mar 2006 A1
20060069178 Rastogi et al. Mar 2006 A1
20060074487 Gilg Apr 2006 A1
20060100701 Esch et al. May 2006 A1
20060111776 Glick et al. May 2006 A1
20060134173 Liu et al. Jun 2006 A1
20060135477 Haitjema et al. Jun 2006 A1
20060212116 Woods Sep 2006 A1
20060238702 Glick et al. Oct 2006 A1
20060241752 Israel Oct 2006 A1
20060271186 Nishi et al. Nov 2006 A1
20070016293 Tran Jan 2007 A1
20070032868 Woods Feb 2007 A1
20070050024 Zhang Mar 2007 A1
20070050025 Nguyen et al. Mar 2007 A1
20070078515 Brady et al. Apr 2007 A1
20070088433 Esch et al. Apr 2007 A1
20070100445 Shadduck May 2007 A1
20070106377 Smith et al. May 2007 A1
20070118216 Pynson May 2007 A1
20070129798 Chawdhary Jun 2007 A1
20070129799 Schedler Jun 2007 A1
20070129800 Cumming Jun 2007 A1
20070129801 Cumming Jun 2007 A1
20070132949 Phelan Jun 2007 A1
20070156236 Stenger Jul 2007 A1
20070213817 Esch et al. Sep 2007 A1
20070260308 Tran Nov 2007 A1
20070260310 Richardson Nov 2007 A1
20080015689 Esch et al. Jan 2008 A1
20080033547 Chang et al. Feb 2008 A1
20080046074 Smith et al. Feb 2008 A1
20080046075 Esch et al. Feb 2008 A1
20080046077 Cumming Feb 2008 A1
20080051886 Lin Feb 2008 A1
20080154364 Richardson et al. Jun 2008 A1
20080200982 Your Aug 2008 A1
20080269887 Cumming Oct 2008 A1
20080300680 Nun Dec 2008 A1
20080306587 Your Dec 2008 A1
20080306588 Smiley Dec 2008 A1
20080306589 Donitzky et al. Dec 2008 A1
20090005865 Smiley et al. Jan 2009 A1
20090027661 Choi et al. Jan 2009 A1
20090043384 Niwa et al. Feb 2009 A1
20090116118 Frazier et al. May 2009 A1
20090125106 Weinschenk, III et al. May 2009 A1
20090149952 Shadduck Jun 2009 A1
20090198326 Zhou et al. Aug 2009 A1
20090204209 Tran Aug 2009 A1
20090204210 Pynson Aug 2009 A1
20090264998 Mentak et al. Oct 2009 A1
20090292355 Boyd et al. Nov 2009 A1
20090319040 Khoury Dec 2009 A1
20100004742 Cumming Jan 2010 A1
20100055449 Ota Mar 2010 A1
20100057095 Khuray et al. Mar 2010 A1
20100094412 Wensrich Apr 2010 A1
20100094413 Rombach et al. Apr 2010 A1
20100131058 Shadduck May 2010 A1
20100131059 Callahan et al. May 2010 A1
20100179653 Argento et al. Jul 2010 A1
20100204787 Noy Aug 2010 A1
20100211169 Stanley et al. Aug 2010 A1
20100228344 Shadduck Sep 2010 A1
20100288346 Esch Sep 2010 A1
20100324672 Esch et al. Dec 2010 A1
20100324674 Brown Dec 2010 A1
20110029074 Reisin et al. Feb 2011 A1
20110071628 Gross et al. Mar 2011 A1
20110118834 Lo et al. May 2011 A1
20110118836 Jain May 2011 A1
20110208301 Anvar et al. Aug 2011 A1
20110224788 Webb Sep 2011 A1
20110264209 Wiechmann et al. Oct 2011 A1
20110282442 Scholl et al. Nov 2011 A1
20110288638 Smiley et al. Nov 2011 A1
20120016473 Brady et al. Jan 2012 A1
20120035724 Clarke Feb 2012 A1
20120071972 Zhao Mar 2012 A1
20120078364 Stenger Mar 2012 A1
20120095125 Hu et al. Apr 2012 A1
20120150292 Mentak et al. Jun 2012 A1
20120232649 Cuevas Sep 2012 A1
20120245683 Christie et al. Sep 2012 A1
20120253458 Geraghty et al. Oct 2012 A1
20120253459 Reich et al. Oct 2012 A1
20120290084 Coroneo Nov 2012 A1
20120296423 Caffey Nov 2012 A1
20120296424 Betser Nov 2012 A1
20120310341 Simonov et al. Dec 2012 A1
20120310343 Van Noy Dec 2012 A1
20130006353 Betser et al. Jan 2013 A1
20130035760 Portney Feb 2013 A1
20130038944 Chang et al. Feb 2013 A1
20130040073 Pett et al. Feb 2013 A1
20130060331 Shadduck Mar 2013 A1
20130110234 DeVita et al. May 2013 A1
20130110235 Shweigerling May 2013 A1
20130116781 Nun May 2013 A1
20130131794 Smiley et al. May 2013 A1
20130190867 Peyman Jul 2013 A1
20130231741 Clarke Sep 2013 A1
20130250239 Hildebrand et al. Sep 2013 A1
20130268070 Esch et al. Oct 2013 A1
20130297018 Brady et al. Nov 2013 A1
20130317607 DeBoer et al. Nov 2013 A1
20130317608 Hermans et al. Nov 2013 A1
20140012277 Matthews et al. Jan 2014 A1
20140058507 Reich et al. Feb 2014 A1
20140085726 Portney Mar 2014 A1
20140100654 Portney et al. Apr 2014 A1
20140107459 Lind et al. Apr 2014 A1
20140111765 DeBoer et al. Apr 2014 A1
20140121768 Simpson May 2014 A1
20140135917 Glazier May 2014 A1
20140135918 De Juan, Jr. et al. May 2014 A1
20140142558 Culbertson et al. May 2014 A1
20140172089 Lee et al. Jun 2014 A1
20140172092 Carson et al. Jun 2014 A1
20140180403 Silvestrini et al. Jun 2014 A1
20140180404 Tram Jun 2014 A1
20140180405 Weinschenk, III et al. Jun 2014 A1
20140180406 Simpson Jun 2014 A1
20140180407 Sohn et al. Jun 2014 A1
20140180410 Gerardi Jun 2014 A1
20140227437 DeBoer et al. Aug 2014 A1
20140228949 Argento et al. Aug 2014 A1
20140249625 Shadduck Sep 2014 A1
20140257478 McCafferty Sep 2014 A1
20140257479 McCafferty Sep 2014 A1
20140296977 Culbertson et al. Oct 2014 A1
20140309734 Sohn et al. Oct 2014 A1
20150087743 Anvar et al. Mar 2015 A1
20150105760 Rao et al. Apr 2015 A1
20150127102 Wortz May 2015 A1
20150173892 Borja et al. Jun 2015 A1
20150202041 Shadduck Jul 2015 A1
20150216652 Jansen Aug 2015 A1
20150230980 Culbertson et al. Aug 2015 A1
20150238310 Matthews et al. Aug 2015 A1
20150327991 Hayes Nov 2015 A1
20150342728 Simonov et al. Dec 2015 A1
20150359625 Argal et al. Dec 2015 A1
20150366656 Wortz et al. Dec 2015 A1
20160000558 Honigsbaum Jan 2016 A1
20160008126 Salahieh et al. Jan 2016 A1
20160051361 Phillips Feb 2016 A1
20160058553 Salahieh et al. Mar 2016 A1
20160074154 Woods Mar 2016 A1
20160106534 Deboer et al. Apr 2016 A1
20160113761 Nishi et al. Apr 2016 A1
20160128826 Silvestrini et al. May 2016 A1
20160184089 Dudee et al. Jun 2016 A1
20160184092 Smiley et al. Jun 2016 A1
20160208138 Nishijima et al. Jul 2016 A1
20160256265 Borja et al. Sep 2016 A1
20160262875 Smith et al. Sep 2016 A1
20160281019 Deklippel et al. Sep 2016 A1
20160287380 Shi et al. Oct 2016 A1
20160317287 Silvestrini et al. Nov 2016 A1
20160361157 Honigsbaum Dec 2016 A1
20170020662 Shadduck Jan 2017 A1
20170049561 Smiley et al. Feb 2017 A1
20170049562 Argento et al. Feb 2017 A1
20170100234 Culbertson et al. Apr 2017 A1
20170216021 Brady Aug 2017 A1
20170247525 Silvestrini et al. Aug 2017 A1
20170290658 Hildebrand et al. Oct 2017 A1
20170319332 Kahook et al. Nov 2017 A1
20170348095 Wortz et al. Dec 2017 A1
20180014928 Kahook et al. Jan 2018 A1
20180028308 Smiley et al. Feb 2018 A1
20180085211 Culbertson et al. Mar 2018 A1
20180110613 Wortz et al. Apr 2018 A1
20180125640 Smiley et al. May 2018 A1
20180132997 Smiley et al. May 2018 A1
20180147051 Scholl et al. May 2018 A1
20180153682 Hajela et al. Jun 2018 A1
20180161152 Argento et al. Jun 2018 A1
20180161153 Kahook et al. Jun 2018 A1
20180177589 Argento et al. Jun 2018 A1
20180177639 Rao et al. Jun 2018 A1
20180185139 Sohn et al. Jul 2018 A1
20180256315 Hildebrand et al. Sep 2018 A1
20180271642 Wortz et al. Sep 2018 A1
20180271645 Brady et al. Sep 2018 A1
20180280135 Otts Oct 2018 A1
20180296323 Olcina Portilla Oct 2018 A1
20180307061 State et al. Oct 2018 A1
20180318068 Otts et al. Nov 2018 A1
20180344453 Brady Dec 2018 A1
20180360659 Culbertson et al. Dec 2018 A1
20180368971 Zacher et al. Dec 2018 A1
20180368973 Wortz et al. Dec 2018 A1
20180368974 Kahook et al. Dec 2018 A1
20190000612 Rao et al. Jan 2019 A1
20190015198 Kuiper Jan 2019 A1
20190021848 Kahook et al. Jan 2019 A1
20190069989 Otts et al. Mar 2019 A1
20190076239 Wortz et al. Mar 2019 A1
20190076241 Alarcon Heredia et al. Mar 2019 A1
20190076243 Hadba et al. Mar 2019 A1
20190083235 Wortz Mar 2019 A1
20190099263 Brady et al. Apr 2019 A1
20190269499 Ellis Sep 2019 A1
20190269500 De Juan, Jr. et al. Sep 2019 A1
20190274823 Argento et al. Sep 2019 A1
20190358025 Smiley et al. Nov 2019 A1
20190374333 Shadduck Dec 2019 A1
20190374334 Brady et al. Dec 2019 A1
20200000577 Smiley et al. Jan 2020 A1
20200054445 Rosen et al. Feb 2020 A1
20200129287 Culbertson et al. Apr 2020 A1
20200138564 Culbertson et al. May 2020 A1
20200157124 Silvestrini May 2020 A1
20200179104 Brady et al. Jun 2020 A1
20200261217 Dudee Aug 2020 A1
20200337833 Green Oct 2020 A1
20200345481 Ellis Nov 2020 A1
20200369853 Silvestrini et al. Nov 2020 A1
20200397562 Cady Dec 2020 A1
20210007554 Byun et al. Jan 2021 A1
20210015303 Byun et al. Jan 2021 A1
20210015359 Goldshleger et al. Jan 2021 A1
20210030530 Smiley et al. Feb 2021 A1
20210038373 Collins et al. Feb 2021 A1
20210063767 Hong et al. Mar 2021 A1
20210093447 Heckler et al. Apr 2021 A1
20210100649 Smiley Apr 2021 A1
20210100650 Smiley et al. Apr 2021 A1
20210100652 Walz et al. Apr 2021 A1
20210113327 Auld et al. Apr 2021 A1
20210128195 Abt May 2021 A1
20210128516 Cheng et al. May 2021 A1
20210128800 Chon et al. May 2021 A1
20210154957 Olson et al. May 2021 A1
20210191153 Borja et al. Jun 2021 A1
20210191154 Borja et al. Jun 2021 A1
20210196890 Appy et al. Jul 2021 A1
20210196893 Appy et al. Jul 2021 A1
20210196894 Appy et al. Jul 2021 A1
20210196900 Appy et al. Jul 2021 A1
20210205134 Rao et al. Jul 2021 A1
20210220067 Charles Jul 2021 A1
20210228333 Hubschman et al. Jul 2021 A1
20210244488 Carbone et al. Aug 2021 A1
20210251718 Tripathi Aug 2021 A1
20210259827 Brady et al. Aug 2021 A1
20210282920 Cady Sep 2021 A1
20210284944 Grandhi et al. Sep 2021 A1
20210290369 Cady Sep 2021 A1
20210290370 Cady Sep 2021 A1
20210290371 Anvar et al. Sep 2021 A1
20210290374 Kahook et al. Sep 2021 A1
20210291469 Zheng et al. Sep 2021 A1
20210292557 Cheng et al. Sep 2021 A1
20210292558 Bassampour et al. Sep 2021 A1
20210297560 Luna et al. Sep 2021 A1
20210302625 Cheng et al. Sep 2021 A1
20210315688 Matthews Oct 2021 A1
20210322151 Kahook et al. Oct 2021 A1
20210322219 Raksi Oct 2021 A1
20210361415 Borja et al. Nov 2021 A1
20210369106 Campin et al. Dec 2021 A1
20210369446 Taber et al. Dec 2021 A1
20210371150 Leibold et al. Dec 2021 A1
20210401570 Brady et al. Dec 2021 A1
20220000606 Cady Jan 2022 A1
20220015946 Hallen et al. Jan 2022 A1
20220047383 Brady et al. Feb 2022 A1
Foreign Referenced Citations (100)
Number Date Country
1064611 Sep 1992 CN
102186438 Sep 2011 CN
102271623 Dec 2011 CN
20 2010 003217 Aug 2011 DE
0356050 Feb 1990 EP
0766540 Aug 1999 EP
1 852 090 Jan 2009 EP
1 859 760 Apr 2010 EP
2 451 380 Mar 2014 EP
2 473 137 Mar 2014 EP
2 111 822 Aug 2014 EP
1881818 Jul 2015 EP
2 512 374 Nov 2015 EP
2 501 336 Sep 2016 EP
3 049 023 Jun 2017 EP
3 035 889 Feb 2019 EP
3 171 821 Mar 2020 EP
3 463 186 Aug 2020 EP
3 003 217 Oct 2020 EP
3 782 584 Feb 2021 EP
3 651 693 May 2021 EP
3 197 396 Sep 2021 EP
3 888 595 Oct 2021 EP
3 932 367 Jan 2022 EP
3946 155 Feb 2022 EP
H09-150002 Jun 1997 JP
2005-511201 Apr 2005 JP
2006-511245 Apr 2006 JP
2006-516002 Jun 2006 JP
2007-313326 Dec 2007 JP
2010-514507 May 2010 JP
2011-526822 Oct 2011 JP
2013-047290 Mar 2013 JP
WO 9217132 Oct 1992 WO
WO 9929266 Jun 1999 WO
WO 1999056670 Nov 1999 WO
WO 2000021467 Apr 2000 WO
WO 2001034067 May 2001 WO
WO 2004037127 May 2004 WO
WO 2004052242 Jun 2004 WO
WO 2004054471 Jul 2004 WO
WO 2004072689 Aug 2004 WO
WO 2006047383 May 2006 WO
WO 2007005778 Jan 2007 WO
WO 2007047529 Apr 2007 WO
WO 2007047530 Apr 2007 WO
WO 2008024766 Feb 2008 WO
WO 2008031231 Mar 2008 WO
WO 2008077040 Jun 2008 WO
WO 2008082957 Jul 2008 WO
WO 2008103798 Aug 2008 WO
WO 2009015161 Jan 2009 WO
WO 2009015226 Jan 2009 WO
WO 2009015234 Jan 2009 WO
WO 2009015240 Jan 2009 WO
WO 2009064876 May 2009 WO
WO 2010010565 Jan 2010 WO
WO 2010081093 Jul 2010 WO
WO 2011026068 Mar 2011 WO
WO 2011106435 Sep 2011 WO
WO 2011137191 Nov 2011 WO
WO 2012006616 Jan 2012 WO
WO 2012129407 Sep 2012 WO
WO 2013016804 Feb 2013 WO
WO 2013070924 May 2013 WO
WO 2013142323 Sep 2013 WO
WO 2013166068 Nov 2013 WO
WO 2013180254 Dec 2013 WO
WO 2013190130 Dec 2013 WO
WO 2014099630 Jun 2014 WO
WO 2014145562 Sep 2014 WO
WO 2014152017 Sep 2014 WO
WO 2014197170 Dec 2014 WO
WO 2015066502 May 2015 WO
WO 2015066532 May 2015 WO
WO 2015126604 Aug 2015 WO
WO 2015148673 Oct 2015 WO
WO 2016018932 Feb 2016 WO
WO 2016033217 Mar 2016 WO
WO 2016049059 Mar 2016 WO
WO 2016122805 Aug 2016 WO
WO 2016201351 Dec 2016 WO
WO 2017079449 May 2017 WO
WO 2017079733 May 2017 WO
WO 2017087358 May 2017 WO
WO 2017096087 Jun 2017 WO
WO 2017192855 Nov 2017 WO
WO 2017205811 Nov 2017 WO
WO 2018081595 May 2018 WO
WO 2018119408 Jun 2018 WO
WO 2018167099 Sep 2018 WO
WO 2018222579 Dec 2018 WO
WO 2018227014 Dec 2018 WO
WO 2019005859 Jan 2019 WO
WO 2019027845 Feb 2019 WO
WO 2019089515 May 2019 WO
WO 2019236908 Dec 2019 WO
WO 2021092222 May 2021 WO
WO 2021119174 Jun 2021 WO
WO 2021126451 Jun 2021 WO
Non-Patent Literature Citations (15)
Entry
Extended European Search Report and Opinion dated Jan. 20, 20157 for EP Application No. 14857916.2. (9 pages).
International Search Report and Written Opinion dated Feb. 11, 2015 for PCT/US2014/063538. (6 pages).
Aliancy, et al., “Long-term capsule clarity with a disk-shaped intraocular lens”, Journal of Cataract & Refractive Surgery, Apr. 2018, vol. 44, Issue 4, pp. 504-509.
Ehrmann, et al., “Biomechanical analysis of the accommodative apparatus in primates”, Clinical and Experimental Optometry, May 2008, vol. 91, Issue 3, pp. 302-312.
Ehrmann, et al., “Ex Vivo Accommodation Simulator II—Concept and Preliminary Results”, Proceedings of SPIE vol. 5314, Ophthalmic Technologies XIV, Jul. 2004, pp. 48-58.
Gabel, et al., “Silicone oil with high specific gravity for intraocular use”, British Journal of Ophthalmology, Apr. 1987, vol. 71, 262-267.
Ghallagher-Wetmore, et al., “Supercritical fluid processing: a new dry technique for photoresist developing”, SPIE's 1995 Symposium on Microlithography, 1995, vol. 2438, 16 pages.
Kramer, et al., “Prevention of postoperative capsular bag opacification using intraocular lenses and endocapsular devices maintaining an open or expanded capsular bag”, Journal of Cataract & Refractive Surgery, Mar. 2016, vol. 42, Issue 3, pp. 469-484.
Lane, et al., “Comparison of the biomechanical behavior of foldable intraocular lenses”, Journal of Cataract Refract Surg, Nov. 2004, vol. 30, pp. 2397-2402.
Leishman, et al., “Prevention of capsular bag opacification with a modified hydrophilic acrylic disk-shaped intraocular lens”, Journal of Cataract & Refractive Surgery, Sep. 2012, vol. 38, Issue 9, pp. 1664-1670.
Nakamura, et al., “Analysis and Fractionation of Silicone and Fluorosilicone Oils for Intraocular Use”, Investigative Ophthalmology & Visual Science, vol. 31, No. 10, Oct. 1990, 2059-2069.
National Center for Biotechnology Information. PubChem Substance Database; SID=184590955, https://pubchem.ncbi.nlm.nih.gov/substance/184590955 (accessed Sep. 20, 2017).
Zhang, et al., “Fluidic adaptive lens with high focal length tunability”, Applied Physics Letters, May 2003, vol. 82, No. 19, pp. 3171-3172.
Zhang, et al., “Integrated fluidic adaptive zoom lens”, Optics Letters, Dec. 2004, vol. 29, No. 24, pp. 2855-2857.
Zhao, et al., “Strategies for Supercritical CO2 Fractionation of Polydimethylsiloxane,” Journal of Applied Polymer Science, 1995, vol. 55, 773-778.
Related Publications (1)
Number Date Country
20200085568 A1 Mar 2020 US
Provisional Applications (1)
Number Date Country
61899110 Nov 2013 US
Continuations (3)
Number Date Country
Parent 16207658 Dec 2018 US
Child 16694968 US
Parent 15144544 May 2016 US
Child 16207658 US
Parent PCT/US2014/063538 Oct 2014 US
Child 15144544 US